doi:10.3969/j.issn.1673-8640.2023.12.017

Abstract

CLC Number:

R446.1

Figures/Tables 6

References 8

[1]	张成飞, 翟甜甜, 张岩钊, 等. 血清半乳甘露聚糖试验对非粒细胞缺乏患者侵袭性肺曲霉病的诊断价值评估及影响因素分析[J]. 中华医院感染学杂志, 2018, 28(9):1284-1287.
[2]	TERRERO-SALCEDO D, POWERS-FLETCHER M V. Updates in laboratory diagnostics for invasive fungal infections[J]. J Clin Microbiol, 2020, 58(6):e01487-19.
[3]	中国医师协会血液科医师分会, 中国侵袭性真菌感染工作组. 血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第六次修订版)[J]. 中华内科杂志, 2020, 59(10):754-763.
[4]	张传明, 曹泓宇, 孙继德, 等. 血清和支气管肺泡灌洗液GM试验对非粒细胞缺乏患者不同类型肺曲霉病的诊断价值分析[J]. 中国真菌学杂志, 2022, 17(2):146-151.
[5]	李文钢, 陈贤, 唐山. GM试验联合痰真菌培养对侵袭性真菌感染的诊断价值[J]. 中外医学研究, 2021, 19(29):60-62.
[6]	LIU L, GU Y, WANG Y, et al. The clinical characteristics of patients with nonneutropenic invasive pulmonary aspergillosis[J]. Front Med(Lausanne), 2021, 8:631461.
[7]	任增花, 徐凌. 侵袭性肺曲霉菌病诊断方法的研究进展[J]. 中国临床医学, 2018, 25(6):1009-1015.
[8]	杨玉琪, 雷玲玲, 周磊, 等. G试验和GM试验联合无菌体液真菌培养检测对侵袭性念珠菌病的诊断效果评估[J]. 中南药学, 2022, 20(5):1048-1052.

真菌名称	例数	百分比/%	GM平均值/（μg/L）
烟曲霉	56	35.0	4.2
黄曲霉	13	8.1	3.8
黑曲霉	5	3.1	3.6
其他曲霉	3	1.9	4.0

真菌名称	例数	百分比/%	GM平均值/（μg/L）
烟曲霉	56	35.0	4.2
黄曲霉	13	8.1	3.8
黑曲霉	5	3.1	3.6
其他曲霉	3	1.9	4.0

GM 试验	临床诊断		合计
GM 试验	阳性	阴性	合计
阳性	58	38	96
阴性	14	50	64
合计	72	88	160

GM 试验	临床诊断		合计
GM 试验	阳性	阴性	合计
阳性	58	38	96
阴性	14	50	64
合计	72	88	160

真菌培养	临床诊断		合计
真菌培养	阳性	阴性	合计
阳性	48	29	77
阴性	29	54	83
合计	77	83	160

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 6

References 8

Related Articles 15

Recommended Articles

Metrics

联合诊断	临床诊断		合计
联合诊断	阳性	阴性	合计
阳性	82	28	110
阴性	2	48	50
合计	84	76	160

检测方法	敏感性	特异性
GM试验	68.2（58/85）	66.7（50/75）
痰液真菌培养	56.5（48/85）	72.0（54/75）
2种方法联合	96.5（82/85）	64.0（48/75）

患者临床结局	例数	治疗前GM/（μg/mL）	治疗后GM
患者临床结局	例数	治疗前GM/（μg/mL）	第1次/ （μg/mL）	第2次/ （μg/mL）
治愈	72	4.2	2.0	0.8
死亡	8	6.1	8.2	10.6

[1]	DUAN Pengcang, DONG Ruifang, LIU Xiaoman, CAO Yang, WANG Ruoxi. Correlation between serum Trx2，P-tau and total magnetic resonance imaging load score and cognitive function in patients with cerebral small vessel disease [J]. Laboratory Medicine, 2024, 39(1): 1-6.
[2]	ZHANG Miaomiao, DUAN Dongkui, YU Chun, WANG Lina. Expression and prognostic assessment value of miR-924 and SLC1A5 in lung cancer tissues [J]. Laboratory Medicine, 2024, 39(1): 13-18.
[3]	ZHANG Yang, ZHANG Dehe, TANG Shiyue, ZHANG Jun, WANG Jianming, CHEN Ling. Predictive value of soluble CD163 combined with Charlson index for esophageal variceal bleeding in patients with liver cirrhosis [J]. Laboratory Medicine, 2024, 39(1): 19-25.
[4]	LIU Bohan, LIU Yiwen, HE Yiqing, LU Renquan, DU Yan, ZHANG Guoliang, GUO Qian, GAO Feng, YANG Cuixia. Serum amphiregulin and mesothelin in auxiliary diagnosis of breast cancer [J]. Laboratory Medicine, 2024, 39(1): 26-30.
[5]	LAI Yuanyuan, HE Zhenye, SHEN Huaqing, LIN Yiteng, LIU Xijun, QI Jun, LIN Yongping. Roles of TAT，PIC and thromboelastography for assessing coagulation function in tumor patients [J]. Laboratory Medicine, 2024, 39(1): 43-46.
[6]	ZHANG Xiaoling, JIN Yao, LI Sufang, PENG Haiying. Synergistic diagnosis of THR mRNA and ALCAT1 in hyperthyroidism heart disease [J]. Laboratory Medicine, 2024, 39(1): 60-67.
[7]	. [J]. Laboratory Medicine, 2024, 39(1): 68-70.
[8]	LAN Jun, LU Shuting, YANG Jianrui. Roles of serum IL-26 and IL-27 levels in patients with colorectal cancer [J]. Laboratory Medicine, 2024, 39(1): 7-12.
[9]	JIANG Haoqin, XU Qianqian, XU Liming, GUAN Ming. Homogenization management and practice of clinical blood and body fluid determinations [J]. Laboratory Medicine, 2024, 39(1): 95-99.
[10]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[11]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[12]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[13]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[14]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[15]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.